2 studies found for:    Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Into
Show Display Options
Rank Status Study
1 Completed A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Conditions: Crohn's Disease;   IBD;   Colitis;   Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg;   Drug: Group 3: ustekinumab approximately 6 mg/kg;   Drug: Group 1: Placebo
2 Active, not recruiting A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
Conditions: Crohn's Disease;   Colitis;   IBD;   Inflammatory Bowel Disease
Interventions: Drug: Placebo SC;   Drug: Placebo IV;   Drug: Ustekinumab 90 mg SC;   Drug: Ustekinumab 130 mg IV

Indicates status has not been verified in more than two years